Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical calcipotriol for wound healing in dystrophic epidermolysis bullosa
2016-001967-35Phase 2Terminated
- Sponsor
- University Hospital of Dermatology, Paracelsus Medical University
- Start
- Jun 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of calcipotriol in dystrophic epidermolysis bullosa (DEB) (2 arms), sponsored by University Hospital of Dermatology, Paracelsus Medical University. Primary endpoint: Wound area reduction. Started Jun 2016; status: terminated.
02
Drugs
calcipotriol
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on 2016-001967-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001967-35.